Evaluating molecular changes in brain metastases
Evaluation of the Humoral and Tumoral Molecular Alteration Profile of Brain Metastases
NA · GCS Ramsay Santé pour l'Enseignement et la Recherche · NCT05848050
This study is testing how changes in genes and other molecules in brain tumors can help doctors understand them better and find better treatments for patients with these tumors.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | GCS Ramsay Santé pour l'Enseignement et la Recherche (other) |
| Locations | 1 site (Marseille) |
| Trial ID | NCT05848050 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze the molecular alteration profiles of brain metastases by comparing them to liquid biopsies obtained from blood and lumbar punctures. It focuses on identifying mutations, gene amplifications, and epigenetic changes through high-throughput sequencing and transcriptome analysis. The study is designed as a single-center, prospective, interventional exploration, requiring only a blood test and lumbar puncture from eligible patients. The goal is to enhance understanding of the genomic landscape of brain metastases and improve treatment strategies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 or over with cerebral metastases from a solid cancer that can be surgically excised.
Not a fit: Patients with contraindications to surgery, lumbar puncture, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with brain metastases.
How similar studies have performed: While this approach is exploratory, similar studies have shown promise in understanding molecular profiles in other cancer types, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 or over; * Patient with cerebral metastases from a solid cancer, at least one of which is accessible to surgical excision (contrast enhancement of at least 1 cm); * Patient able to understand the information related to the study and to read the information leaflet; * Patient having signed a written informed consent to participate in the study. Exclusion Criteria: * Patient with a medical contraindication to surgery and anesthesia; * Patient whose anatomical location of the cerebral metastasis contraindicates wide resection; * Patient with a contraindication to performing a lumbar puncture; * Pregnant, parturient or breastfeeding women; * Patient participating in another clinical trial, or in a period of exclusion from another clinical trial; * Patient under guardianship or curatorship, or under a regime of deprivation of liberty; * Patient not benefiting from a social security scheme.
Where this trial is running
Marseille
- Hôpital Privé Clairval — Marseille, France (RECRUITING)
Study contacts
- Study coordinator: Philippe MD METELLUS
- Email: philippe.metellus@outlook.fr
- Phone: 491171483
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Brain Metastases